XORTX Therapeutics Inc. Share Price & Technical Analysis
XRTX · $2.34 (+7.34%)
Healthcare / Biotechnology
$2.34
+7.34%
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment o…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-21% return in May, -6% avg return in past 3 year May month.
-12% return in 2026, -101% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -11% | -20% | -5% | 45% | -21% | – | – | – | – | – | – | – | -12% |
| 25 | -14% | 2% | 0% | 11% | -8% | -4% | -20% | 11% | 8% | -29% | 7% | -10% | -46% |
| 24 | 3% | 19% | 19% | -33% | -2% | -24% | -5% | 22% | -19% | -16% | -11% | -19% | -65% |
| 23 | -36% | -9% | -21% | 35% | -10% | -8% | 2% | 5% | -7% | -49% | -90% | -3% | -192% |
| 22 | -27% | -11% | 42% | -31% | 4% | 8% | -1% | -1% | -18% | -34% | -2% | -7% | -77% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$3.73M
P/E ratio
—
52W high
$7.05
52W low
$1.73
Volume
30,344
Beta
0.22
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is XORTX Therapeutics Inc. share price today?
- XORTX Therapeutics Inc. (XRTX) last traded around $2.34 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does XRTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for XRTX. Download the app for real-time alerts.
- How can I analyze XORTX Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.